WO2000039154A8 - Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie - Google Patents

Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie

Info

Publication number
WO2000039154A8
WO2000039154A8 PCT/DE1999/004112 DE9904112W WO0039154A8 WO 2000039154 A8 WO2000039154 A8 WO 2000039154A8 DE 9904112 W DE9904112 W DE 9904112W WO 0039154 A8 WO0039154 A8 WO 0039154A8
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
preeclampsia
receptor
malign
hypertension
Prior art date
Application number
PCT/DE1999/004112
Other languages
English (en)
French (fr)
Other versions
WO2000039154A3 (de
WO2000039154A2 (de
Inventor
Gerd Wallukat
Volker Homuth
Friedrich Luft
Original Assignee
Max Delbrueck Centrum
Gerd Wallukat
Volker Homuth
Friedrich Luft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19954305A external-priority patent/DE19954305A1/de
Application filed by Max Delbrueck Centrum, Gerd Wallukat, Volker Homuth, Friedrich Luft filed Critical Max Delbrueck Centrum
Priority to EP99967916A priority Critical patent/EP1141018A2/de
Priority to AU24291/00A priority patent/AU2429100A/en
Priority to US09/868,967 priority patent/US7745139B1/en
Priority to CA002363999A priority patent/CA2363999A1/en
Priority to JP2000591065A priority patent/JP2002539075A/ja
Publication of WO2000039154A2 publication Critical patent/WO2000039154A2/de
Publication of WO2000039154A3 publication Critical patent/WO2000039154A3/de
Publication of WO2000039154A8 publication Critical patent/WO2000039154A8/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die Erfindung betrifft Peptide des AT1-Rezeptors und ihre Verwendung zur Elimination von spezifisch bindenden, zellphysiologisch aktiven, pathologischen Antikörpern bei Präeklampsie sowie für ihren diagnostischen Nachweis. Bevorzugt sind Peptide mit der Sequenz AFHYESQ, AVHYQSN, SHFYQTR, GYYFDTN oder ENTNIT.
PCT/DE1999/004112 1998-12-24 1999-12-22 Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie WO2000039154A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP99967916A EP1141018A2 (de) 1998-12-24 1999-12-22 Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie
AU24291/00A AU2429100A (en) 1998-12-24 1999-12-22 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension
US09/868,967 US7745139B1 (en) 1998-12-24 1999-12-22 Peptides of the AT1 receptor and their uses
CA002363999A CA2363999A1 (en) 1998-12-24 1999-12-22 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension
JP2000591065A JP2002539075A (ja) 1998-12-24 1999-12-22 At1受容体のペプチド、及び子癇前症、悪性高血圧症におけるその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19860320.7 1998-12-24
DE19860320 1998-12-24
DE19954305A DE19954305A1 (de) 1998-12-24 1999-11-11 Peptide des AT¶1¶-Rezeptors und ihre Verwendung, insbesondere für die Diagnostider Präeklampsie
DE19954305.4 1999-11-11

Publications (3)

Publication Number Publication Date
WO2000039154A2 WO2000039154A2 (de) 2000-07-06
WO2000039154A3 WO2000039154A3 (de) 2000-09-21
WO2000039154A8 true WO2000039154A8 (de) 2001-02-15

Family

ID=26051071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/004112 WO2000039154A2 (de) 1998-12-24 1999-12-22 Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie

Country Status (5)

Country Link
EP (1) EP1141018A2 (de)
JP (1) JP2002539075A (de)
AU (1) AU2429100A (de)
CA (1) CA2363999A1 (de)
WO (1) WO2000039154A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2314811A1 (en) * 2000-08-02 2002-02-02 Brian Archibald Macvicar Autoimmunity to angiotensin at1 receptors in schizophrenia
DE10123929A1 (de) * 2001-05-11 2002-11-21 Celltrend Gmbh Verfahren zur Vorhersage eines Transplantatabstoßungsrisikos und immunologischer Testkit
EP1570272A2 (de) 2002-11-29 2005-09-07 Max-Delbrück-Centrum Für Molekulare Medizin Bestimmung agonistischer autoantikörper
DE10327066A1 (de) * 2002-11-29 2004-09-16 Max-Delbrück-Centrum für Molekulare Medizin Bestimmung agonistischer Autoantikörper
PL1884775T3 (pl) 2006-08-04 2010-06-30 Celltrend Gmbh Sposób rozpoznawania chorób związanych z przeciwciałem przeciwko receptorowi AT 1
EP1884776A1 (de) 2006-08-04 2008-02-06 Celltrend GmbH Verfahren zur diagnose einer krankheit, die auf der gegenwart des anti-endothelin-antikörpers beruht
CN109467599B (zh) * 2017-09-08 2021-06-04 武汉华纪元生物技术开发有限公司 短肽atr001以及由短肽制备具有偏向性调节at1r功能的单克隆抗体和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025482A1 (en) * 1993-04-23 1994-11-10 Evans Herbert J Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
DE19826442A1 (de) * 1998-06-02 1999-12-09 Affina Immuntechnik Gmbh Rational designte Peptide, ihre Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
AU2429100A (en) 2000-07-31
JP2002539075A (ja) 2002-11-19
CA2363999A1 (en) 2000-07-06
WO2000039154A3 (de) 2000-09-21
EP1141018A2 (de) 2001-10-10
WO2000039154A2 (de) 2000-07-06

Similar Documents

Publication Publication Date Title
WO2000005249A3 (en) Synthetic peptides and methods of use for autoimmune disease therapies
EP1071460A4 (de) Internalisierende erb2 antikörper
WO2003057134A8 (en) Specific binding agents of human angiopoietin-2
WO2000023564A3 (en) Protein design automation for protein libraries
WO2004062475A3 (en) Fluorescent assays for protein kinases
WO1999011791A3 (en) Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2001098357A3 (en) Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
WO2001049728A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO2001036487A3 (en) Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2003003004A3 (en) Method for identifying compounds the specifically deplete mast cells
GB9807256D0 (en) Functional protein compositions,emulsions based thereon and processes for their preparation
AUPP589598A0 (en) Novel peptides
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
WO2000039154A3 (de) Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie
WO2005000207A3 (en) Pcdgf receptor antibodies and methods of use thereof
AU739516C (en) Novel lantibiotic related to actagardine, and processes for the preparation and use thereof
WO2000066731A3 (en) Recombinant laminin 5
WO2002072606A3 (en) Epitope testing using hla
WO2002026929A3 (en) Kini-3 motor protein and methods for its use
WO2001019870A3 (en) Secreted soluble alpha2delta-2, alpha2delta-3, alpha2delta-4 calcium channel subunit polypeptides and screening assays using same
WO1998024896A3 (en) Muteins of obese protein
AU2002322515A1 (en) Compositions, methods, and kits related to treating and diagnosing hypertension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ DM EE GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ DM EE GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ DM EE GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LV MA MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 27/2000 UNDER (81) ADD "MA, TZ"

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 591065

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999967916

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2363999

Country of ref document: CA

Ref country code: CA

Ref document number: 2363999

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999967916

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09868967

Country of ref document: US